What are the indications for dual antiplatelet therapy (DAPT) and apixaban after cardiac surgery?

Indications for DAPT and Apixaban Post Cardiac Surgery

After cardiac surgery, dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is indicated for 12 months in patients who underwent CABG for acute coronary syndrome (ACS), while apixaban is indicated only for atrial fibrillation, venous thromboembolism, or DVT prophylaxis—not for coronary artery disease or graft protection. 1, 2

DAPT After Cardiac Surgery

Primary Indications for DAPT Post-CABG

For ACS patients undergoing CABG:

• Continue DAPT (aspirin + P2Y12 inhibitor) for 12 months post-operatively 1
• This applies whether the ACS was managed with PCI and stenting or CABG alone
• Resume the P2Y12 inhibitor as soon as possible after surgery when bleeding risk allows 1

Choice of P2Y12 inhibitor:

• Ticagrelor is preferred over clopidogrel in ACS patients unless bleeding risk outweighs ischemic benefit 1
• Clopidogrel is acceptable in patients with prior intracranial bleeding or those who cannot tolerate ticagrelor 1
• Prasugrel is contraindicated in patients ≥75 years, body weight <60 kg, or history of stroke/TIA 1

Evidence Supporting DAPT Post-CABG

Recent data shows DAPT after elective CABG reduces all-cause mortality (OR 0.43) and cardiovascular mortality (OR 0.30) compared to aspirin alone, though with increased major bleeding (OR 1.48) 3. The 2025 ESC consensus emphasizes that ticagrelor plus aspirin for 1 year reduces vein graft failure but increases clinically important bleeding 4, 5.

Critical timing consideration: Do not discontinue DAPT within the first month after surgery in patients who were on DAPT pre-operatively 1. Continue aspirin perioperatively if bleeding risk allows 1.

Apixaban After Cardiac Surgery

FDA-Approved Indications for Apixaban

Apixaban has no indication for coronary artery disease or post-CABG graft protection 2. The FDA-approved indications are:

1. Atrial fibrillation: Reduce stroke/systemic embolism risk in nonvalvular AF 2
2. DVT prophylaxis: After hip or knee replacement surgery 2
3. VTE treatment: Treatment of DVT/PE and reduction of recurrence 2

When Apixaban May Be Used Post-Cardiac Surgery

If the patient has concurrent atrial fibrillation:

• Apixaban is appropriate for stroke prevention in AF patients post-cardiac surgery 2
• Standard dosing: 5 mg twice daily (or 2.5 mg twice daily if patient meets dose-reduction criteria: age ≥80, weight ≤60 kg, or creatinine ≥1.5 mg/dL with at least 2 of these factors) 2

Critical contraindication: Combining apixaban with DAPT significantly increases bleeding risk and should only occur in highly selected patients with acute vascular disease 6. The 2024 ESC AF guidelines explicitly state that adding antiplatelet treatment to anticoagulation is not recommended in AF patients to prevent recurrent embolic stroke 6.

Key Clinical Scenarios

Scenario 1: Post-CABG for ACS without AF

• Use: DAPT (aspirin + ticagrelor or clopidogrel) for 12 months 1
• Avoid: Apixaban has no role here 2

Scenario 2: Post-CABG for stable CAD without AF

• Use: Aspirin monotherapy is standard 1
• Consider: DAPT may reduce mortality even in elective cases based on recent evidence, but bleeding risk must be carefully weighed 3
• Avoid: Apixaban has no role 2

Scenario 3: Post-CABG with concurrent atrial fibrillation

• Use: Apixaban for AF (per FDA indication) 2
• DAPT consideration: If patient also had ACS, the combination of apixaban + DAPT dramatically increases bleeding risk 6
• Practical approach: In the first 12 months post-ACS/CABG, consider triple therapy (apixaban + aspirin + clopidogrel) only if absolutely necessary, then transition to apixaban + single antiplatelet agent, then apixaban alone 6

Scenario 4: Elective valve surgery without CAD

• Use: Anticoagulation per valve type (mechanical vs bioprosthetic)
• Apixaban: Not FDA-approved for mechanical valves; may be used for bioprosthetic valves with AF 2

Critical Pitfalls to Avoid

Do not use antiplatelet drugs as substitutes for anticoagulation in AF: Aspirin and clopidogrel are inferior to apixaban for stroke prevention in AF (HR 0.45 favoring apixaban) 6, 2. This is a common error in elderly patients.

Do not routinely combine apixaban with antiplatelet therapy without clear indication: This combination occurs frequently in practice without adequate justification and increases bleeding without clear benefit for stroke or death prevention 6.

Do not inappropriately dose-reduce apixaban: 41% of patients initiated on apixaban 2.5 mg for AF receive potentially inappropriate doses 7. Verify dose-reduction criteria are met.

Proton pump inhibitor use: When using DAPT, prescribe a PPI to reduce GI bleeding risk 1. Pantoprazole or rabeprazole have lower drug-drug interaction potential than omeprazole/esomeprazole 1.